In secondary MN, treatment centers on removal of the underlying cause, after which there is often a complete remission of proteinuria within several months.

PROGNOSIS

Patients with idiopathic MN who experience either spontaneous or drug-induced remission have an excellent prognosis, and the majority of patients who receive immunosuppression achieve complete or partial remission. Relapse, however, occurs in up to 30%, requiring repeat rounds of immunosuppression.

The patients who do not achieve long-term remission may experience a progressive, sometimes rapid, decline in renal function that can progress to ESRD. If a transplant is performed, the risk of MN recurring in the allograft is approximately 10% to 15%.